Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1996-08-01
1998-11-24
Rollins, John W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 78, 424450, 536 21, 536 51, 530300, 530331, 530329, A01N 3718, A01N 5726
Patent
active
058406743
ABSTRACT:
This invention provides novel methods and reagents for specifically delivering biologically active compounds to phagocytic mammalian cells. The invention also relates to specific uptake of such biologically active compounds by phagocytic cells and delivery of such compounds to specific sites intracellularly. The invention specifically relates to methods of facilitating the entry of antiviral and antimicrobial drugs and other agents into phagocytic cells and for targeting such compounds to specific organelles within the cell. The invention specifically provides compositions of matter and pharmaceutical embodiments of such compositions comprising conjugates of such antimicrobial drugs and agents covalently linked to particulate carriers generally termed microparticles. In particular embodiments, the antimicrobial drug is covalently linked to a microparticle via an organic linker molecule which is the target of a microorganism-specific protein having enzymatic activity. Thus, the invention provides cell targeting of drugs wherein the targeted drug is only released in cells infected with a particular microorganism. Alternative embodiments of such specific drug delivery compositions also contain polar lipid carrier molecules effective in achieving intracellular organelle targeting in infected phagocytic mammalian cells. Particular embodiments of such conjugates comprise antimicrobial drugs or agents covalently linked both to a microparticle via an organic linker molecule and to a polar lipid compound, to facilitate targeting of such drugs or agents to particular subcellular organelles within the cell. Also provided are porous microparticles impregnated with antiviral and antimicrobial drugs and agents wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Also provided are nonporous microparticles coated with an antiviral or antimicrobial drug and further coated wherein the surface or outside extent of the microparticle is covered with a degradable coating that is specifically degraded within an infected phagocytic mammalian cell. Methods of inhibiting, attenuating, arresting, combating and overcoming microbial infection of phagocytic mammalian cells in vivo and in vitro are also provided.
REFERENCES:
patent: 4780455 (1988-10-01), Liberman et al.
patent: 4793986 (1988-12-01), Serino et al..
patent: 4847240 (1989-07-01), Ryser et al.
patent: 5053394 (1991-10-01), Ellestad et al.
patent: 5258453 (1993-11-01), Kopecek et al.
Afzelius et al., Biochim. Biophys. Acta 979: 231-238 (1989).
Alvarez-Doninquez et al., "Role of Complement Component C1q in Phagocytosis of Listeria monocytogenes by Murine Macrophage-Like Cell Lines,"Infect. Immun. 61: 3664-3672 (1993).
Anderson et al., J Am. Chem. Soc. 85: 3039 (1963).
Ashborn et al., "Anti-HIV Activity of CD4-Pseudomonas Exotoxin on Infected Primary Human Lympocytes and Monocyte/Macrophages," J Infect. Dis. 163: 703-709 (1991).
Baer, Can. J Biochem. Phys. 34: 288-304 (1955).
Bai and Amidon, "Structural Specificity of Mucosal-Cell Transport and Metabolism of Peptide Drugs: Implications for Oral Peptide Drug Delivery," Pharm. Res. 9: 969-978 (1992).
Bai et al., "Utilization of Peptide Carrier System to Improve Intestinal Absorption: Targeting Prolidase as a Prodrug-Converting Enzyme," J Pharm. Sci. 81: 113-116 (1992).
Baroni et al., "Expression of HIV in Lymph Node Cells of LAS Patients: Immunohistology, In Situ Hybridization, and Identification of Target Cells," Am. J Pathol. 133: 498-506 (1988).
Berdel et al., Lipids 22: 943-946 (1987).
Bickel et al., "Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery," Proc. Natl. Acad. Sci. USA 90: 2618-2622 (1993).
Blakey, "Drug Targeting with Monoclonal Antibodies," Acta Oncol. 31: 91-97 (1992).
Blight et al., "Detection of hepatitis C virus RNA by in situ hybridization," Liver 12: 286-289 (1992).
Blum et al., "Bloood clearance and organ deposition of intravenously administered colloidal particles: the effects of particle size, nature and shape," Int. J Pharm. 12: 135-146 (1982).
Boman et al., "Cell-free immunity in Cecropia: A model system for antibacterial proteins," Eur. J. Biochem. 201: 23-31 (1990).
Borissova et al., "Biodegradable Microspheres. 17. Lysosomal Degradation of Primaquine-Peptide Spacer Arms," Journal of Pharmaceutical Sciences, vol. 84, No. 2, Feb. 1995, pp. 256-262.
Brewster et al., "Improved Delivery through Biological Membranes XXXI: Solubilization and Stabilization of an Estradiol Chemical Delivery System by Modified .beta.-Cyclodextrins," J Pharm. Sci. 77: 981-985 (1985).
Bromberg et al., "Detection of Borditella pertussis Associated with the Alveolar Macrophages of Children with Human Immunodeficiency Virus Infection," Infect. Immun. 59: 4715-4719 (1991).
Brown & Silvius, Biochim. Biophys. Acta 1023: 341-351 (1990).
Buchmeier and Heffron, "Induction of Salmonella Stress Proteins upon Infection of Macrophages," Science 248: 730-732 (1990).
Chang, "Leishmania donovani: Promastigote-Macrophage Surface Interactions in Vitro," Exp. Parisitol. 48: 175-189 (1979).
Clarke et al., "Detection of HIV-1 in human lung macrophages using the polymerase chaine reaction," AIDS 4: 1133-1136 (1990).
Comiskey & Heath, Biochim. Biophys. Acta 1024: 307-317 (1990).
Cordier et al., "In vivo Activation of Alveolar Macrophages in Ovine Lentivirus Infection," Clin. Immunol. Immunopathol. 55: 355-367 (1990).
Couveur and Puisieux, "Nano-and microparticles for the delivery of polypeptides and proteins," Adv. Drug Deliv. Rev. 10: 141-162 (1993).
Debs et al., Biochim. Biophys. Acta 901: 183-190 (1987).
Dreyer et al., Proc. Natl. Acad. Sci. USA 86: 9752-9756 (1989).
Duncan, "Drug-polymer conjugates: potential for improved chemotherapy," Anticancer Drugs 3: 175-210 (1992).
Embretson et al., "Massive covert infection of helper T lympohocytes and macrophages by HIV during the incubation period of AIDS," Nature 362: 359-361 (1993).
Faulk et al., "Transferrin-Adriamycin Conjugates which Inhibit Tumor Cell Proliferation without Interaction with DNA Inhibit Plasma Membrane Oxidoreductase and Proton Release in K562 Cells," Biochem. Int. 25: 815-822 (1991).
Franssen et al., "Low Molecular Weight Proteins as Carrier for Renal Drug Targeting: Preparation of Drug-Protein Conjugates and Drug-Spacer Derivatives and Their Catabolism in Renal Cortex Homogenates and Lysosomal Lysates," J Med. Chem. 35: 1246-1259 (1992).
Frehel et al., Intramacrophage Growth of Mycobacterium avium during Infection of Mice, Infect. Immun. 59: 2207-2214 (1991).
Friedman et al., "Uptake and Intracellular Survival of Bordatella pertussis in Human Macrophages," Infect. Immun. 60: 4578-4585 (1992).
Gaspar et al., "Drug targeting with polyalkylcyanoacrylate nanoparticles: in vitro activity of primaquine-loaded nanoparticles against intracellular Leishmania donovani," Ann. Trop. Med. Parasitol. 86: 41-49 (1992).
Gendelman et al., "Slow, persistent replication of lentiviruses: Role of tissue macrophages and macrophage precursors in bone marrow," Proc. Natl. Acad. Sci. USA 82: 7086-7090 (1985).
Groisman et al., "Resistance to host antimicrobial peptides is necessary for Salmonella virulence," Proc. Natl. Acad. Sci. USA 89: 11939-11943 (1992).
Halstead et al., "Dengue Viruses and Mononuclear Phagocytes: I. Infection Enhancement by Non-Neutralizing Antibody," J Exp. Med. 146: 201-217 (1977).
Hashimoto et al., Biochim. Biophys. Acta 816: 163-168 (1985).
Hashimoto et al., Biochim. Biophys. Acta 816: 169-178 (1985).
Heath and Martin, Chem. Phys. Lipids 40: 347-358 (1986).
Heath et al., Biochim. Biophys. Acta 862: 72-80 (1986).
Heath, Methods in Enzymol. 149: 111-119.
Heinrich et al., "In-vivo Release of a GnRH Agonist from a Slow-release Poly(lactide-glycolide) Copolymer Preparation: Comparison in Rat, Rabbit and Guniea-Pig," J Pharm. Pharmacol. 43: 762-765 (1991).
Horwitz and Maxfield, "Legionella pneumphila Inhibits Acidification of its Phagosome in Human Monocytes," J Cell Biol. 99: 1936-1943 (1984).
Horwitz, "Inter
Gallicchio Vincent S.
Meredith Michael J.
Stowell Michael H. B.
Yatvin Milton B.
Oregon Health & Sciences University
Rollins John W.
LandOfFree
Covalent microparticle-drug conjugates for biological targeting does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Covalent microparticle-drug conjugates for biological targeting, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Covalent microparticle-drug conjugates for biological targeting will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1702094